Media Coverage

Proteomics International Laboratories has signed a licence agreement to sell its PromarkerD predicti...

Dr Kirsten Peters, Head of Clinical Studies at Proteomics International (ASX: PIQ), was interviewed ...

Proteomics International (ASX:PIQ) featured on Channel 7’s 4pm and 6pm news bulletins discussing Pro...

Dr Richard Lipscombe, Managing Director of Proteomics International (ASX: PIQ), recently featured in...

Proteomics International Laboratories is nudging closer to commercialising its PromarkerD predictive...

Dr Richard Lipscombe, Managing Director of Proteomics International (ASX: PIQ), recently had an inte...

Dr Richard Lipscombe, Managing Director of Proteomics International (ASX: PIQ), was featured on 6PR ...

Proteomics International’s Managing Director, Dr Richard Lipscombe, featured on Channel 9’s 5pm news...

Proteomics International Laboratories’ blood test uses biomarkers to diagnose oesophageal adenocarci...

Proteomics International Laboratories’ (Proteomics International) blood test uses biomarkers – prote...

Proteomics International Managing Director Dr Richard Lipscombe said the prototype test, named Proma...

Proteomics International’s Managing Director, Dr Richard Lipscombe, featured on 6PR Afternoons on th...

Proteomics International Laboratories’ share price has hit a seven-month high after a United States ...

Proteomics International Laboratories soared 13 per cent after its shares came out of voluntary trad...

Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce a major milestone in the ...

Proteomics International Pty Ltd has developed a new blood-based diagnostic test called the Promarke...

Proteomics International managing director Dr Richard Lipscombe said the technology has the potentia...

Proteomics International Laboratories has revealed new results showing that refinement of its simple...

“We’ve refined our diagnostic models to correctly identify 89 per cent of patients with oesophageal ...

Proteomics International Laboratories’ 66 per cent-owned subsidiary OxiDx has been granted a breakth...

Article: Intervention needed to stop kidney disease overwhelming NHS, charity says

Article: NHS facing ‘impossible’ challenge to care for kidney disease patients, charity says

Article: Kidney disease ‘could become public health emergency’ without more funding, charity warns

Article: Heartbreaking impact of endometriosis on women laid bare

Dr Richard Lipscombe, Managing Director of Proteomics International, spoke with ABN Newswire regardi...

Article: Proteomics International (ASX:PIQ) inks exclusive licence agreement to bring PromarkerD to ...

Article: Proteomics’ PromarkerD test enters the lucrative US market

Article: Proteomics seals exclusive deal for kidney test in US

Proteomics International is pleased to announce it has signed an exclusive licence agreement with So...

We are excited to present the latest results for our potential world’s first non-invasive blood test...

Proteomics International in collaboration with Janssen Research & Development have shown that Promar...

“The new members bring a wealth of knowledge in treating diabetes patients and they will be importan...

We are pleased to announce the appointment of additional members to the Clinical Advisory Board addi...

“To mark the end of Endometriosis Awareness Month, experienced Health Research Associate Dr Kirsten ...

“Proteomics International Laboratories says it has developed a simple new blood test to identify up ...

We are pleased to announce the latest results for our potential new world-first blood test for diagn...

Proteomics International Laboratories Ltd is pleased to provide a copy of the Q&A session with inves...

The Company advises that it is in the closing stages of finalising the detailed terms of its Exclusi...

“Whilst the process of finalising the terms of the Exclusive Licence Agreement has taken the parties...

We are pleased to announce the extension of our distribution agreement with medical diagnostics comp...

“The two companies began working together in November 2021 and initially signed a two-year licence a...

The Company is pleased to announce the American Medical Association has approved a new dedicated CPT...